ES2189766T3 - Pyrazolo (4,3-d)ipiridmidinas. - Google Patents

Pyrazolo (4,3-d)ipiridmidinas.

Info

Publication number
ES2189766T3
ES2189766T3 ES00960511T ES00960511T ES2189766T3 ES 2189766 T3 ES2189766 T3 ES 2189766T3 ES 00960511 T ES00960511 T ES 00960511T ES 00960511 T ES00960511 T ES 00960511T ES 2189766 T3 ES2189766 T3 ES 2189766T3
Authority
ES
Spain
Prior art keywords
carbon atoms
mean
hal
groups
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00960511T
Other languages
English (en)
Spanish (es)
Inventor
Rochus Jonas
Hans-Michael Eggenweiler
Pierre Schelling
Maria Christadler
Norbert Beier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Application granted granted Critical
Publication of ES2189766T3 publication Critical patent/ES2189766T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES00960511T 1999-09-06 2000-08-24 Pyrazolo (4,3-d)ipiridmidinas. Expired - Lifetime ES2189766T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19942474A DE19942474A1 (de) 1999-09-06 1999-09-06 Pyrazolo[4,3-d]pyrimidine

Publications (1)

Publication Number Publication Date
ES2189766T3 true ES2189766T3 (es) 2003-07-16

Family

ID=7920966

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00960511T Expired - Lifetime ES2189766T3 (es) 1999-09-06 2000-08-24 Pyrazolo (4,3-d)ipiridmidinas.

Country Status (23)

Country Link
US (1) US6777419B1 (enExample)
EP (1) EP1210349B1 (enExample)
JP (1) JP4975921B2 (enExample)
KR (1) KR20020025253A (enExample)
CN (1) CN1145627C (enExample)
AR (1) AR025569A1 (enExample)
AT (1) ATE231866T1 (enExample)
AU (1) AU773878B2 (enExample)
BR (1) BR0013781A (enExample)
CA (1) CA2384037C (enExample)
CZ (1) CZ294587B6 (enExample)
DE (2) DE19942474A1 (enExample)
DK (1) DK1210349T3 (enExample)
ES (1) ES2189766T3 (enExample)
HU (1) HUP0202624A3 (enExample)
MX (1) MXPA02002383A (enExample)
NO (1) NO20021083D0 (enExample)
PL (1) PL353366A1 (enExample)
PT (1) PT1210349E (enExample)
RU (1) RU2249594C2 (enExample)
SK (1) SK3132002A3 (enExample)
WO (1) WO2001018004A2 (enExample)
ZA (1) ZA200202653B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10031584A1 (de) 2000-06-29 2002-01-10 Merck Patent Gmbh 5-Aminoalkyl-pyrazolo[4,3-d]pyrimidine
DE10058662A1 (de) * 2000-11-25 2002-05-29 Merck Patent Gmbh Verwendung von Pyrazolo[4,3-d]pyrimidinen
PL362513A1 (en) * 2000-12-19 2004-11-02 Merck Patent Gmbh Pharmaceutical formulation containing pyrazolo[4,3-d]pyrimidines and antithrombotic agents, calcium-antagonists, prostaglandins or prostaglandin derivatives
DE10103647A1 (de) * 2001-01-27 2002-08-01 Merck Patent Gmbh Verfahren zur Herstellung eines Pyrazolo (4,3-d) pyrimidinderivates
DE10148883A1 (de) * 2001-10-04 2003-04-10 Merck Patent Gmbh Pyrimidinderivate
EP1620437B1 (en) 2003-04-29 2009-06-17 Pfizer Limited 5,7-diaminopyrazolo¬4,3-d pyrimidines useful in the traetment of hypertension
US7572799B2 (en) * 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
GB0327323D0 (en) * 2003-11-24 2003-12-31 Pfizer Ltd Novel pharmaceuticals
ATE417849T1 (de) * 2004-04-07 2009-01-15 Pfizer Pyrazoloä4,3-düpyrimidine
EP1881985B1 (en) 2005-05-12 2010-12-29 Pfizer, Inc. Anhydrous crystalline forms of n-ý1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl¨methanesulfonamide
NL2000291C2 (nl) 2005-11-10 2009-02-17 Pfizer Prod Inc 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.
CA2831634C (en) * 2011-04-21 2019-11-12 Origenis Gmbh Pyrazolo [4,3-d] pyrimidines useful as kinase inhibitors
CZ308056B6 (cs) * 2015-07-20 2019-11-27 Ustav Experimentalni Botaniky Av Cr V V I 5-Substituované-7-[4-(substituované)benzyl]amino-3-isopropylpyrazolo[4,3-d]pyrimidiny, jejich použití jako antirevmatika, a farmaceutické přípravky
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
RU2020118913A (ru) 2017-12-14 2022-01-14 Х. Лундбекк А/С (H. Lundbeck A/S) Виды комбинированного лечения, предусматривающего введение 1h-пиразолo[4,3-b]пиридинов
US11535611B2 (en) 2017-12-20 2022-12-27 H. Lundbeck A/S Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors
US10766893B2 (en) * 2017-12-20 2020-09-08 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256650A (en) * 1989-03-29 1993-10-26 Merrell Dow Pharmaceuticals Inc. Selective adenosine receptor agents
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
DE19644228A1 (de) * 1996-10-24 1998-04-30 Merck Patent Gmbh Thienopyrimidine
AU730670B2 (en) * 1997-04-25 2001-03-08 Pfizer Limited Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP PDE5) for the treatment of sexual dysfunction
DE19752952A1 (de) * 1997-11-28 1999-06-02 Merck Patent Gmbh Thienopyrimidine
DE10031584A1 (de) * 2000-06-29 2002-01-10 Merck Patent Gmbh 5-Aminoalkyl-pyrazolo[4,3-d]pyrimidine
DE10058662A1 (de) * 2000-11-25 2002-05-29 Merck Patent Gmbh Verwendung von Pyrazolo[4,3-d]pyrimidinen
DE10060388A1 (de) * 2000-12-05 2002-06-06 Merck Patent Gmbh Verwendung von Pyrazolo [4,3-d]pyrimidinen
DE10103647A1 (de) * 2001-01-27 2002-08-01 Merck Patent Gmbh Verfahren zur Herstellung eines Pyrazolo (4,3-d) pyrimidinderivates

Also Published As

Publication number Publication date
CN1377357A (zh) 2002-10-30
RU2249594C2 (ru) 2005-04-10
DE50001191D1 (de) 2003-03-06
AR025569A1 (es) 2002-12-04
BR0013781A (pt) 2002-05-14
DE19942474A1 (de) 2001-03-15
PT1210349E (pt) 2003-06-30
PL353366A1 (en) 2003-11-17
HUP0202624A3 (en) 2004-11-29
CZ294587B6 (cs) 2005-02-16
JP2003508534A (ja) 2003-03-04
HUP0202624A2 (hu) 2002-12-28
ZA200202653B (en) 2003-09-23
DK1210349T3 (da) 2003-05-19
EP1210349B1 (de) 2003-01-29
CA2384037C (en) 2009-10-13
CN1145627C (zh) 2004-04-14
MXPA02002383A (es) 2002-09-02
KR20020025253A (ko) 2002-04-03
AU7279300A (en) 2001-04-10
WO2001018004A2 (de) 2001-03-15
EP1210349A2 (de) 2002-06-05
CA2384037A1 (en) 2001-03-15
ATE231866T1 (de) 2003-02-15
NO20021083L (no) 2002-03-05
WO2001018004A3 (de) 2001-08-09
AU773878B2 (en) 2004-06-10
NO20021083D0 (no) 2002-03-05
CZ2002736A3 (cs) 2002-05-15
JP4975921B2 (ja) 2012-07-11
US6777419B1 (en) 2004-08-17
SK3132002A3 (en) 2002-07-02

Similar Documents

Publication Publication Date Title
ES2189766T3 (es) Pyrazolo (4,3-d)ipiridmidinas.
ES2192183T3 (es) Derivados de imidazopiridina como inhibidores de fosfodiesterasa vii.
ES2037243T3 (es) Tiazolidindionas como agentes hipoglicemicos y anti-ateroscleroticos.
AR035284A1 (es) Formulaciones en combinacion de derivados de propanol-amina sustituidos con arilo, junto con otras sustancias activas y su utilizacion
CO5011050A1 (es) Tienopirimidinas
MX9102407A (es) 4 arilpiperazinas y 4-arilpiperidinas novedosas.
ECSP034914A (es) "azaindoles"
ES2057010T3 (es) Derivados de cromano.
ES2105525T3 (es) 2-fenil-3-aroilbenzotiofenos antiestrogenicos como agentes hipoglicemicos.
UY29047A1 (es) Derivados de sulfonamidas, su preparación y su aplicación en terapéutica
ES2107148T3 (es) Composicion tintorea, por oxidacion, de fibras queratinicas, que comprende un para-aminofenol, un meta-aminofenol y una para-fenilendiamina y/o una bis-fenilalquilendiamina.
ES2083348T3 (es) Derivado de 2-(2-amino-1,6-dihidro-6-oxo-purin-9-il)metoxi-1,3-propandiol.
AR031774A1 (es) Nuevos derivados de diaminopirazol y su utilizacion en tintura de oxidacion de las fibras queratinicas
ES463409A1 (es) Procedimiento para la preparacion de nuevas fluoracil-resor-cinas sustituidas.
AR030537A1 (es) Acidos quinolincarboxilicos y naftiridincarboxilico antibacterianos
AR064188A1 (es) Derivados de indolizina, procesos de obtencion y composiciones farmaceuticas que los contienen.
ES2182489T3 (es) Sales de calcio de antibioticos lipopeptidicos, procedimiento para su preparacion y utilizacion.
AR029343A1 (es) USO DE UN ANTAGONISTA DE NMDA DE BAJA AFINIDAD PARA EL TRATAMIENTO DE LA DEPRESIoN
UY24010A1 (es) Nuevos pirrolocarbazoles
SV1999000006A (es) Nuevas sulfonamidas naftil- y anilido-substituidas ref. lea 32809-sv
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica
EA200100852A1 (ru) Производные резорцина
ES2143833T3 (es) Acidos y esteres de la diosmetina y composiciones farmaceuticas que los contienen.
ES2125537T3 (es) Arilbenzoilguanidinas.
MX9304820A (es) Derivados de 1, 4-benzodioxano, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.